Novartis reveals new drug to fight malaria resistance and transmission

Swiss pharmaceutical giant Novartis has unveiled a next-generation malaria treatment that not only demonstrates a 97% cure rate but also blocks disease transmission, representing a potential breakthrough in combating drug-resistant strains of the deadly parasite.

Developed using high-speed robotic screening of millions of compounds in San Diego, the drug GanLum achieved a 97% cure rate in a study involving 1,700 patients across 12…